

Fecha del CVA	12/02/2020
---------------	------------

Parte A. DATOS PERSONALES

Nombre y Apellidos	Raúl J. Andrade Bellido		
DNI	24849596M	Edad	63
Núm. identificación del investigador	Researcher ID		
	Scopus Author ID	35481447600	
	Código ORCID	0000-0002-1565-0757	

A.1. Situación profesional actual

Organismo	Institute of Biomedical Research in Malaga (IBIMA) - University of Malaga- Hospital Virgen de la Victoria		
Dpto. / Centro			
Dirección	Boulevard Louis Pasteur, 29010		
Teléfono	952131615	Correo electrónico	andrade@uma.es
Categoría profesional	PROFESSOR OF MEDECINE (2008)/DIRECTOR DIGESTIVE UNIT (2010)/DIRECTOR DEPARTMENT OF MEDICINE (2013)	Fecha inicio	
Espec. cód. UNESCO	320000 - Ciencias Médicas		
Palabras clave	Medicina clínica; Terapéutica; Toxicología		

A.2. Formación académica (título, institución, fecha)

Licenciatura/Grado/Doctorado	Universidad	Año
PHD in Medicine & Surgery	Universidad de Málaga	1989
Hepatologist	MINISTERIO DE EDUCACION Y CIENCIA	1987

A.3. Indicadores generales de calidad de la producción científica

Parte B. RESUMEN LIBRE DEL CURRÍCULUM

Raúl J. Andrade is Professor of Medicine and Director of the Department of Medicine at the University of Malaga. Director of the Unidad de Gestión Clínica of Ap Digestivo, University Hospital of Málaga. Founder and director of the Spanish Drug Induced Liver Injury (DILI) Registry (www.spanishdili.uma.es)-the first network specialized in the study of Drug Induced Liver Injury- and of the Spanish Latin-American DILI Network and the recently set-up Prospective European DILI Registry awarded by the European Association for the Study of the Liver (EASL). Appointed by the EASL as Chairman of the Clinical Practice Guidelines Council responsible for writing a new CPG on Drug Induced Liver Injury 2016. Chair of CIOMS (Council for International Organizations of Medical Sciences) working group on DILI 2017. Chair COST ACTION CA17112. Principal investigator of CIBERehd group. He leads the PAIDI CTS-1032 group, IP of IBIMA Group on Translational Clinical Pharmacology Expert of the European Medicines Agency (EMA) and the Spanish Medicines Agency in the Evaluation of liver safety of drugs. Member of the steering committee of the Standardization Phenotype Project of the International Serious Adverse Event Consortium and the steering committee of the Group of Special Interest in Hepatotoxicity (AASLD). Member of the working team on the Cholestatic and Drug-induced Liver Disease section of the EASL- HEPAMAP project. He is member of the expert panel of the EFSA (European Food Safety Authority) since 2016. Member of the Reviewing board for the EASL International Liver Congress (2013-2016). We are partner of the TRANSBIOLINE IMI 2018 project, and the COST grant proposal Prospective European Drug-Induced Liver Injury Network. Invited speaker in international meetings such as: Gordon Research Conference, Maine, USA (2008); NIH Workshop: Drug-Induced Injury: Standardization of nomenclature and causality assessment (Maryland, USA 2008); EASL Postgraduate course Cholestatic disease of the liver and bile ducts, (Berlin,

Alemania 2011); EASL – IASL JOINT SYMPOSIUM: Drug Induced Liver Disease: Global perspective, (London 2014); Co-Chair Meet-The Professor Lunch at the AASLD(Boston, USA 2014); SYMPOSIUM OF THE IUPHAR-CD - EACPT: "Clinical Networks and Consortia in Drug-Induced Liver Injury (DILI): an opportunity for advancing Safety Sciences" (Madrid, 2015); EASL/AASLD Monothematic Conference on Autoimmune Hepatitis (London, 2015); Japan Digestive Disease Week (Tokyo, 2015); 5th Symposium Hepatology 2015 on Drug-Induced Liver Injury (Switzerland, 2015); EASL Monothematic Conference on NASH (Riga, Latvia 2016); the AASLD Liver Meeting (Boston, USA, 2016). The 26th Conference of the APASL (Shanghai 2017); International Conference on Fatty Liver (Sevilla, Spain 2017); EASL Monothematic Conference Cholangiocytes in health and Disease: from basic Science to novel treatments (Oslo, Norway 2017). He is Associate editor of Liver International (Q1) and member of the editorial board of: Hepatology (2012-2016) (D1) and Frontiers in Pharmacology (Q1), He published over 250 articles in peer-review journals, and 43 book chapters. He has an h-index of 44 and 8761 total citations by 5568 documents. 23 publications were cited more than 100 times and 40 original articles received more than 50 citations. He presented more than 340 communications in International & National Scientific Meetings. In the past 5 years, he has directed 10 PhD thesis included 2 international thesis.

Parte C. MÉRITOS MÁS RELEVANTES (ordenados por tipología)

C.1. Publicaciones

- 1 Artículo científico.** CIRULLI ET; et al. (22/4). 2019. A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. *Gastroenterology* (D1: 2/84). W B SAUNDERS CO-ELSEVIER INC. 156-6, pp.1707-1716. ISSN 0016-5085.
- 2 Artículo científico.** CHURCH RJ; et al. (23/20). 2019. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort. *Hepatology* (D1: 5/84). WILEY. 69-2, pp.760-773. ISSN 0270-9139.
- 3 Artículo científico.** AMPUERO J; et al. (38/32). 2019. Development and Validation of Hepamet Fibrosis Scoring System-a Simple, Non-invasive Test to Identify Patients With Nonalcoholic Fatty liver Disease With Advanced Fibrosis. *Clinical Gastroenterology and Hepatology* (D1: 8/84). ELSEVIER SCIENCE INC. 18-1, pp.216-225. ISSN 1542-3565.
- 4 Artículo científico.** TORRES S; et al. (18/13). 2019. Endoplasmic Reticulum Stress-Induced Upregulation of STARD1 Promotes Acetaminophen-Induced Acute Liver Failure. *Gastroenterology* (D1: 2/84). W B SAUNDERS CO-ELSEVIER INC. 157-2, pp.552-568. ISSN 0016-5085.
- 5 Artículo científico.** SHEN T; et al. (30/12). 2019. Incidence and Etiology of Drug-Induced Liver Injury in Mainland China. *Gastroenterology* (D1: 2/84). W B SAUNDERS CO-ELSEVIER INC. 156-8, pp.2230-2241. ISSN 0016-5085.
- 6 Artículo científico.** ESTEBAN R; et al. (22/11). 2018. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With HCV genotype 3 Infection and Cirrhosis. *Gastroenterology* (D1: 2/84). W B SAUNDERS CO-ELSEVIER INC. 155-4, pp.1120-1127. ISSN 0016-5085.
- 7 Artículo científico.** INMACULADA MEDINA-CALIZ; et al. (25/25). 2018. Herbal and dietary supplement-induced liver injury in the Spanish DILI Registry *Clinical Gastroenterology and Hepatology* (D1: 8/84). ELSEVIER SCIENCE INC. 16, pp.1495-1502. ISSN 1542-3565.
- 8 Artículo científico.** Zoubek ME.; et al. (12/12). 2018. High Prevalence of Ibuprofen Drug-Induced Liver Injury in Spanish and Latin-American Registries *Clin Gastroenterol Hepatol.* (D1: 8/84). ELSEVIER SCIENCE INC. 16-2, pp.292-294. ISSN 1542-3565.
- 9 Artículo científico.** AMPUERO J; et al. (29/19). 2018. Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C *Journal of Hepatology* (D1: 3/84). ELSEVIER SCIENCE BV. 68-5, pp.940-948. ISSN 0168-8278.
- 10 Artículo científico.** Kullak-Ublick GA.; et al. (7/2). 2017. Drug-induced liver injury: recent advances in diagnosis and risk assessment *GUT* (D1: 2 de 80). BMJ PUBLISHING GROUP. 66-6, pp.1154-1164. ISSN 0017-5749.
- 11 Artículo científico.** Medina-Caliz I; et al. (30/30). 2016. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury *Journal of Hepatology* (D1 : 3 de 84). (Posicion 30 de 30, senior). 65-3, pp.532-542. ISSN 0168-8278.

- 12 **Artículo científico**. CHEN M.; et al. (5/4). 2015. Drug-Induced liver injury: interactions between drug properties and host factors *Journal of Hepatology* (D1: 3 de 84; CORRESPONDING AUTHOR).63-2, pp.503-514. ISSN 0168-8278.
- 13 **Artículo científico**. ROBLES-DIAZ M.; et al. 2015. The value of serum aspartate aminotransferase and gamma-glutamyl transpeptidase when calculating type of liver injury in hepatotoxicity.*Liver International* (Q1, 13 de 76). (Posición 17 de 17). 35-11, pp.2474-2482. ISSN 1478-3223.
- 14 **Artículo científico**. PAOLA NICOLETTI; et al. (19/7). 2019. Drug-induced injury due to flucloxacillin: relevance of multiple HLA alleles.*Clinical Pharmacology & Therapeutics* (D1: 15/267). WILEY. 106-1, pp.245-253. ISSN 0009-9236.
- 15 **Artículo científico**. GONZALEZ-JIMENEZ A; et al. (13/13). 2019. The influence of drug properties and host factors on delayed onset of symptoms in Drug-Induced Liver Injury.*Liver international* (Q1: 16/84). WILEY. 39-2, pp.401-410. ISSN 1478-3223.
- 16 **Artículo científico**. ROBLES-DIAZ, M; et al. (20/20). 2015. Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids *Alimentary Pharmacology & Therapeutics* (D1: 10/267).(Posición 20 de 20, senior, Editorial acompañante).. 41-1, pp.116-125. ISSN 0269-2813.
- 17 **Informe científico-técnico**. RAÚL J. ANDRADE. CHAIR. 2019. *EASL Clinical Practice Guidelines: Drug-induced liver injury* (D1: 3/84) *Journal of Hepatology* (D1: 3/84). ELSEVIER SCIENCE BV. 70, pp.1222-1261. ISSN 0168-8278.
- 18 **Informe científico-técnico**. EFSA PANEL ON FOOD ADDITIVES AND NUTRIENT SOURCES ADDED TO FOOD (ANS); et al. 2018. *CLINICAL PRACTICE GUIDELINE. Scientific opinion on the safety of green tea catechins*.EFSA Journal 2018. John Wiley and Sons Ltd. 16-4, pp.1-89.
- 19 **Review**. ANDRADE RJ; et al. (11/1). 2019. Drug-induced liver injury.*Nature Reviews Disease Primers* (D1: 4/160; CORRESPONDING AUTHOR). NATURE PUBLISHING GROUP. 5-1, pp.58-558. ISSN 2056-676X.

C.2. Proyectos

- 1 PI-0310-2018, Análisis integrado de las propiedades farmacológicas, factores del huésped, perfil epigenético y su interacción en el fenotipo clínico y gravedad del daño hepático inducido por fármacos. Consejería de Salud de la Junta de Andalucía. IP Inmaculada Medina Cáliz. (Hospital Clínico Universitario Virgen la Victoria). 01/01/2019-31/12/2021. 30.230,58 €. Miembro de equipo.
- 2 PI18/01804, Evaluation of comedication and trajectories diseases in the modulation of drug-induced liver damage. Instituto de Salud Carlos III. IP Raúl J. Andrade. (Hospital Clínico Universitario Virgen la Victoria). 01/01/2019-31/12/2021. 58.987,5 €. Investigador principal.
- 3 Obtención de contrato de Refuerzo de la Actividad investigadora en las UGC del SAS. Nicolas Monardes SERVICIO ANDALUZ DE LA SALUD. CAN. Eduardo Garcia Fuentes. (Hospital Clínico Universitario Virgen la Victoria). 01/01/2017-31/12/2021.
- 4 UMA18-FEDERJA-193, Evaluación Integrada Mecánica, Diagnóstica y Pronóstica en Hepatotoxicidad. Proyectos I+D+i - Programa Operativo FEDER Andalucía 2014-2020 Universidad de Málaga. Proyectos I+D+i - Programa Operativo FEDER Andalucía 2014-2020. IP Raúl J. Andrade. (Hospital Clínico Universitario Virgen la Victoria). 01/11/2019-31/10/2021. 28.650 €. Investigador principal.
- 5 JR16/00015, Contrato JUAN RODES (JR16/00015) para la UGC de aparato digestivo (convocatoria 2016) Instituto de Salud Carlos III. Mercedes Robles-Diaz. (Hospital Clínico Universitario Virgen la Victoria). 26/01/2017-25/01/2020.
- 6 Contratación temporal de personal laboral técnico de apoyo y de gestión de la I+D+i, en el marco del Sistema Nacional de Garantía Juvenil y del Programa Operativo de Empleo Juvenil 2014 – 2020 Fondo social europeo. Laura Sanz Villanueva. (Universidad de Málaga). 26/01/2018-25/07/2019.
- 7 PI-0285-2016., Valoración de la utilidad de la determinación de micrnas de los exosomas de origen hepático, análisis del perfil inmunitario adaptativo y de la microbiota intestinal en el diagnóstico de hepatotoxicidad idiosincrásica. Miren García Cortés. (Hospital Clínico Universitario Virgen la Victoria). 2017-2019.

- 8 CB07/04/2008, Grupo de hepatopatías asociadas a medicamentos Instituto de Salud Carlos III. Raúl J. Andrade. (Hospital Clínico Universitario Virgen la Victoria). 01/01/2018-31/12/2018. 50.000 €.
- 9 A-0038-2016, Acciones A Intensificación SAS. Refuerzo Anual de la Actividad Investigadora en las Unidades de Gestión Clínica (UGC) del Servicio Andaluz de Salud. A-0038-2016. SERVICIO ANDALUZ DE LA SALUD. CAN. AIDA ORTEGA ALONSO. (Hospital Clínico Universitario Virgen la Victoria). 01/01/2017-31/10/2017.
- 10 Grant Agreement number 523 705, SAFE-T Safer and faster Evidence Based Translation. SAFE-T INTERFACE EUROPE. Innovative Medicines Initiative. IP Raúl J. Andrade. (Hospital Clínico Universitario Virgen la Victoria). 01/01/2011-15/06/2015. 149.400 €. Investigador principal.
- 11 EASL Registry Research Grants Programme. Title: Creation of a European Prospective Drug-Induced Liver Injury Registry (Pro-Euro-DILI Registry). European Association for the Study of the Liver. Raúl J. Andrade. (Hospital Clínico Universitario Virgen la Victoria). 2014-2015. 50.000 €.
- 12 AC-0073-2013, Red andaluza para el estudio de hepatopatías. Consejería de Salud de la Junta de Andalucía. Raúl J. Andrade. (Hospital Clínico Universitario Virgen la Victoria). 2014-2015. 101 €.
- 13 806/5794612, Contrato de colaboración entre la agencia española del medicamento y la universidad de Málaga, a través del departamento de farmacología y de medicina, para el estudio de hepatopatías asociadas a medicamentos. AGENCIA ESPAÑOLA DE MEDICAMENTOS Y PRODUCTOS SANITARIOS. RAÚL J. ANDRADE. (Universidad de Málaga). 15/02/2013-15/09/2014. 42.000 €.
- 14 IMI2- Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease. IP Raúl J. Andrade. (Hospital Clínico Universitario Virgen la Victoria). Desde 2019.
- 15 COST Action CA17112 - Prospective European Drug-Induced Liver Injury Network COST ASSOCIATION AISBL. IP Raúl J. Andrade. (IBIMA-UMA). Desde 2018.

C.3. Contratos

- 1 Research Project Agreement between PREGLEM S.A & RAÚL J. ANDRADE (University of Málaga) entitled: "Ulipristal: analysis of the potential associated risk of liver injury" PREGLEM S.A. 29/03/2019-29/03/2020. 80.000 €.
- 2 Research Project Agreement between Schwabe GmbH and Co. KG & RAÚL J. ANDRADE. "Liver injury by herbal dietary supplements or medicinal products" Willmar Schwabe GmbH and Co. Raúl J. Andrade. 28/03/2019-P10M. 46.550 €.
- 3 Convenio específico de colaboración entre la Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) y la Universidad de Málaga (UMA) para el estudio sobre el registro de hepatopatías asociadas a medicamentos Agencia Española de Medicamentos y Productos Sanitarios. IP MI Lucena. 01/04/2016-P1Y8M10D. 50.820 €.
- 4 International Consortium on Drug Induced Liver Injury (IDILIC). INTERNATIONAL SAE CONSORTIUM LTD.. MI LUCENA. 2010-P3Y.

C.4. Patentes

Aida Ortega Alonso; Raúl J. Andrade; MI Lucena; Andres Gonzalez-Jimenez; Aurelie Papineau. Diseño Aplicación móvil eDILI para uso profesional España. 21/12/2016. Universidad de Málaga.